New entries shake insomnia market's slumber[ ... Read the full report ... ]
FRIDAY, JULY 15, 2005
LONDON The sleeping pill market, long dominated by Sanofi-Aventis's Ambien, is waking up to a rush of new competition.
Improved treatments could double the insomnia market by the end of the decade, but the French company's share of business is set to shrink dramatically, according to industry analysts.
The latest challenger is Takeda Pharmaceutical's Rozerem, or ramelteon, which industry sources say could win approval in the crucial U.S. market as early as next week. The expected approval comes hard on the heels of the successful U.S. debut of Sepracor's Lunesta in April.
Another two competitors - from two U.S. pharmaceutical companies, Pfizer and Merck - are expected in 2006 and 2008, respectively.
Anthony H. Risser | neuroscience | neuropsychology | brain